Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety, tolerability of ES16001, a novel varicella zoster virus reactivation inhibitor, in healthy adults
Funding for this research was provided by:
Genencell Co. Ltd
Received: 16 July 2021
Accepted: 3 August 2021
First Online: 12 August 2021
: This clinical trial (GNC_PT1_2018001) was reviewed and approved by the Ethics Committee of Seoul National University Bundang Hospital, and was performed in accordance with Korean Good Clinical Practice (KGCP). This study is based on the Helsinki Declaration and was conducted with the rights and welfare of the subjects in mind. Prior to screening, all participants provided written informed consent to participate in the study after having been informed about the nature and purpose of the study and participation/withdrawal conditions.
: Not applicable.
: The authors declare that they have no competing interests.